{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959122",
  "id": "02959122",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250617",
  "time": "0936",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kth1v75ydb12.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Commercial Manufacturing Agreement** executed with **SpectronRx** for **64Cu-SAR-bisPSMA**.  \n- **Capacity**: Up to **400,000 patient-ready doses annually** from SpectronRx\u2019s Indiana facility by commercialization.  \n- **Expansion Option**: Potential for additional US sites to scale production further.  \n- **Supply Chain Strategy**: Multi-layered approach combining centralized, regional, and local production, leveraging **copper-64\u2019s 12.7-hour half-life** for extended shelf-life (up to 48 hours).  \n- **Agreement Term**: Initial **5-year period** (effective **17 June 2025**), with standard cancellation/extension terms.  \n- **Commercial Readiness**: Supports large-scale rollout **upon FDA approval** post-Phase III trials (CLARIFY, AMPLIFY).  \n\n**No material financial or capital structure impacts disclosed.**",
  "usage": {
    "prompt_tokens": 2774,
    "completion_tokens": 194,
    "total_tokens": 2968,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:54:31.031683"
}